Markelle Fultz
G· 6'4"· 209· Age 28
Markelle Fultz
#20· G· 6'4"· Age 28
2025-26
Proj.
GP
5
5.4
PPG
0.8
1.1
RPG
0.2
0.3
APG
1.6
1.7
FG%
18.2
0.2
3P%
NaN
0.3
FT%
NaN
0.8
eFG%
18.2
22.5
Markelle Fultz
G | 6'4" | 209 lbs | Age 28
#20 | -
2018 R1 Pick 1 | Washington
Projections
Career Outlook
HOF
<1%
MVP
<1%
All-NBA
<1%
2025-26
Current
Proj.
GP
5
5.4
PPG
0.8
1.1
RPG
0.2
0.3
APG
1.6
1.7
Current
Proj.
FG%
18.2
22.1
3P%
NaN
34.4
FT%
NaN
77.5
eFG%
18.2
22.5
True Talent
Markelle Fultz
No data available
Career Statistics
Latest Projections
| Playing Time | Box Score | Volume | Shooting % | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2029-30 98% ret. | — | 31 | 58.6 | — | 18.7 | 6.9 | 2.2 | 2.9 | 0.9 | 0.2 | 1.1 | 2.8 | 6.0 | 0.7 | 1.9 | 0.6 | 0.8 | 46.2% | 34.4% | 75.4% |
| 2028-29 97% ret. | — | 30 | 54.6 | — | 17.3 | 6.5 | 2.1 | 2.8 | 0.8 | 0.2 | 1.0 | 2.8 | 5.6 | 0.5 | 1.2 | 0.4 | 0.6 | 49.3% | 38.1% | 74.6% |
| 2027-28 94% ret. | — | 29 | 40.9 | — | 15.2 | 5.7 | 1.8 | 2.5 | 0.8 | 0.2 | 1.1 | 2.4 | 5.0 | 0.3 | 0.9 | 0.5 | 0.6 | 48.4% | 37.2% | 81.0% |
| 2026-27 86% ret. | — | 28 | 28.1 | — | 12.6 | 4.4 | 1.4 | 2.3 | 0.6 | 0.1 | 1.0 | 2.0 | 4.1 | 0.1 | 0.4 | 0.3 | 0.5 | 47.6% | 31.9% | 75.2% |
| 2025-26 | TOR | 27 | 5.4 | — | 7.4 | 1.1 | 0.3 | 1.7 | 0.4 | 0.0 | 0.8 | 0.5 | 2.4 | 0.0 | 0.1 | 0.0 | 0.0 | 22.3% | 34.4% | 77.0% |
| 2025-26 | TOR | 27 | 5 | 0 | 7.2 | 0.8 | 0.2 | 1.6 | 0.4 | 0.0 | 0.8 | 0.4 | 2.2 | 0.0 | 0.0 | 0.0 | 0.0 | 18.2% | - | - |
| 2024-25 | SAC | 26 | 21 | 0 | 8.8 | 2.9 | 1.0 | 1.3 | 0.5 | 0.1 | 0.7 | 1.3 | 3.2 | 0.2 | 0.4 | 0.0 | 0.0 | 41.8% | 50.0% | 100.0% |
| 2023-24 | ORL | 25 | 43 | 18 | 21.2 | 7.8 | 3.2 | 2.8 | 1.0 | 0.3 | 1.2 | 3.6 | 7.6 | 0.1 | 0.4 | 0.5 | 0.8 | 47.2% | 22.2% | 69.7% |
| 2022-23 | ORL | 24 | 60 | 60 | 29.6 | 13.9 | 3.9 | 5.7 | 1.4 | 0.4 | 2.3 | 5.8 | 11.3 | 0.5 | 1.4 | 1.9 | 2.4 | 51.4% | 31.0% | 78.3% |
| 2021-22 | ORL | 23 | 18 | 3 | 20.0 | 10.8 | 2.7 | 5.5 | 1.1 | 0.3 | 2.2 | 4.6 | 9.7 | 0.2 | 0.9 | 1.4 | 1.7 | 47.4% | 23.5% | 80.6% |
| 2020-21 | ORL | 22 | 8 | 8 | 26.9 | 12.9 | 3.1 | 5.4 | 1.0 | 0.3 | 2.3 | 5.1 | 13.0 | 0.5 | 2.0 | 2.1 | 2.4 | 39.4% | 25.0% | 89.5% |
| 2019-20 | ORL | 21 | 72 | 60 | 27.7 | 12.1 | 3.3 | 5.1 | 1.3 | 0.2 | 2.0 | 5.0 | 10.7 | 0.5 | 1.9 | 1.6 | 2.2 | 46.5% | 26.7% | 73.0% |
| 2018-19 | ORL | 20 | 19 | 15 | 22.5 | 8.2 | 3.7 | 3.1 | 0.9 | 0.3 | 1.3 | 3.4 | 8.2 | 0.2 | 0.7 | 1.1 | 1.9 | 41.9% | 28.6% | 56.8% |
| 2017-18 | PHI | 19 | 14 | 0 | 18.1 | 7.1 | 3.1 | 3.8 | 0.9 | 0.3 | 1.2 | 3.2 | 7.9 | 0.0 | 0.1 | 0.7 | 1.5 | 40.5% | 0.0% | 47.6% |